Hyderabad's Avra Labs to make Favipiravir for Cipla's Ciplenza ... Jul 28
Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19... Jul 27
India lockdown was it effective ? And how India is gearing up for vaccines read on to understand the recent scenarios... May 01
-Advertisements-